Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Christine M. Cramer-van der Welle, Bas J.M. Peters, Franz M.N.H. Schramel, Olaf H. Klungel, Harry J.M. Groen, Ewoudt M.W. van de Garde. Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018

Member's Comments

No comment yet.

Related content which might interest you: Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020 The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Current challenges in the management of nonsmall cell lung cancer brain metastases Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019 Year: 2020 Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Source: Eur Respir Rev 2014; 23: 79-91 Year: 2014 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017 Year: 2018 Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Possibilities of palliative combined therapy for extensive nonsmall cells lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 378s Year: 2001 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Source: Eur Respir Rev 2014; 23: 92-105 Year: 2014 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017 Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Source: Eur Respir J 2006; 27: 895-901 Year: 2006 Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003